EIKON THERAPEUTICS, INC. (EIKN) Current Ratio
- Current ratio · latest quarter: Value 9.89×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.89× | Current assets / current liabilities. $546.98M ÷ $55.30M ≈ 9.89× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 546.98M USD | Assets, Current |
| Current obligations | 55.30M USD | Liabilities, Current |
| Cash and equivalents | 142.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 388.56M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 6.56M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $546.98M | $55.30M | $142.61M | $388.56M | (m) | (m) | $6.56M | (m) | 9.89× |
| 2026-03-31 | $529.50M | $45.06M | $161.15M | $351.03M | (m) | (m) | $6.00M | (m) | 11.75× |
| 2025-12-31 | $348.92M | $55.01M | $104.90M | $231.07M | (m) | (m) | $681.00K | (m) | 6.34× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |